NBDF/ LinkedIn
Aug 31, 2025, 07:31
Avatrombopag Shows Promise for Pediatric Immune Thrombocytopenia in Late-Stage Global Trial: NBDF
National Bleeding Disorders Foundation shared on LinkedIn:
“Promising news for children and adolescents living with immune thrombocytopenia (ITP). A late-stage global trial shows avatrombopag, an oral treatment already approved for adults, can significantly improve platelet counts and reduce bleeding symptoms in pediatric patients, offering a potential new treatment option for an underserved population.
Learn more about the study results and what they could mean for pediatric ITP care in The Lancet Haematology.”
Stay updated with Hemostasis Today.
-
Jul 27, 2026, 10:33Akshay Kumar Chopra: Exploring Complex Immunohematology Cases at ISBT Academic Day 2026
-
Jul 27, 2026, 09:54Robert Hamilton: A New ”Game-Changing” Approach for Identifying PFOs in Stroke
-
Jul 27, 2026, 08:10Colleen Kelly: Bridging the Access Gap in Gene Therapy for Sickle Cell Disease
-
Jul 27, 2026, 07:59James P. Crowley: A New Era in Cardiovascular Risk Prevention
-
Jul 27, 2026, 07:42Shayan Mohammadmoradi: Leading Membership Growth and Scientific Engagement in ATVB
-
Jul 27, 2026, 07:29Maliheh Davari: Exploring CRISPR Activation for Hemophilia at ISTH 2026
-
Jul 27, 2026, 06:45Maha Othman: The Value of Trusted Scientific Reporting at ISTH 2026
-
Jul 27, 2026, 04:50A Significant Step Forward for People with Bleeding Disorders in the Dominican Republic – WFH
-
Jul 27, 2026, 04:11Mohamed F Doheim: Clarifying the Role of Late IV Thrombolysis in the Era of Endovascular Therapy